Female Reproductive System Neuroendocrine Carcinoma

Female Reproductive System Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 50%
Top sponsor: Novartis Pharmaceuticals
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04635956	Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas	unknown	Phase 2	20	Lei LiOTHER	1	Nov 19, 2020	clinicaltrials

Data updated 22 days agoSource updated Nov 19, 2020source: clinicaltrials